Tango Therapeutics, Inc. (TNGX)
TNGX Stock Price Chart
Explore Tango Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze TNGX price movements and trends.
TNGX Company Profile
Discover essential business fundamentals and corporate details for Tango Therapeutics, Inc. (TNGX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 Sept 2020
Employees
155.00
Website
https://www.tangotx.comCEO
Barbara L. Weber
Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
TNGX Financial Timeline
Browse a chronological timeline of Tango Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.07, while revenue estimate is $41.34M.
Earnings released on 5 Aug 2025
EPS came in at -$0.35 matching the estimated -$0.35, while revenue for the quarter reached $3.18M , missing expectations by -50.34%.
Earnings released on 12 May 2025
EPS came in at -$0.36 falling short of the estimated -$0.34 by -5.88%, while revenue for the quarter reached $5.39M , missing expectations by -15.21%.
Earnings released on 27 Feb 2025
EPS came in at -$0.35 falling short of the estimated -$0.32 by -9.37%, while revenue for the quarter reached $4.12M , missing expectations by -48.64%.
Earnings released on 6 Nov 2024
EPS came in at -$0.27 surpassing the estimated -$0.34 by +20.59%, while revenue for the quarter reached $11.61M , beating expectations by +44.76%.
Earnings released on 7 Aug 2024
EPS came in at -$0.24 surpassing the estimated -$0.34 by +29.41%, while revenue for the quarter reached $19.88M , beating expectations by +167.86%.
Earnings released on 8 May 2024
EPS came in at -$0.35 falling short of the estimated -$0.31 by -12.90%, while revenue for the quarter reached $6.47M , missing expectations by -2.98%.
Earnings released on 18 Mar 2024
EPS came in at -$0.32 falling short of the estimated -$0.28 by -14.29%, while revenue for the quarter reached $5.43M , missing expectations by -34.12%.
Earnings released on 8 Nov 2023
EPS came in at -$0.23 surpassing the estimated -$0.34 by +32.35%, while revenue for the quarter reached $10.73M , beating expectations by +24.50%.
Earnings released on 7 Aug 2023
EPS came in at -$0.23 surpassing the estimated -$0.35 by +34.29%, while revenue for the quarter reached $14.60M , beating expectations by +92.59%.
Earnings released on 9 May 2023
EPS came in at -$0.32 surpassing the estimated -$0.36 by +11.11%, while revenue for the quarter reached $5.77M , missing expectations by -14.07%.
Earnings released on 27 Mar 2023
EPS came in at -$0.33 surpassing the estimated -$0.36 by +8.33%, while revenue for the quarter reached $6.41M , missing expectations by -0.45%.
Earnings released on 10 Nov 2022
EPS came in at -$0.33 falling short of the estimated -$0.32 by -3.13%, while revenue for the quarter reached $6.92M , beating expectations by +22.64%.
Earnings released on 10 Aug 2022
EPS came in at -$0.28 surpassing the estimated -$0.33 by +15.15%, while revenue for the quarter reached $5.77M , beating expectations by +1.97%.
Earnings released on 11 May 2022
EPS came in at -$0.29 falling short of the estimated -$0.28 by -3.57%, while revenue for the quarter reached $5.76M , missing expectations by -1.31%.
Earnings released on 28 Mar 2022
EPS came in at -$0.25 surpassing the estimated -$0.28 by +10.71%, while revenue for the quarter reached $5.72M , missing expectations by -13.06%.
Earnings released on 9 Nov 2021
EPS came in at -$0.28 matching the estimated -$0.28, while revenue for the quarter reached $6.79M , beating expectations by +8.33%.
Earnings released on 6 Aug 2021
EPS came in at -$0.05 , while revenue for the quarter reached $18.15M .
Earnings released on 17 Jul 2021
EPS came in at -$0.14 , while revenue for the quarter reached $6.39M .
Earnings released on 31 Mar 2021
EPS came in at -$0.42 , while revenue for the quarter reached $9.14M .
Earnings released on 13 Nov 2020
EPS came in at -$0.31 , while revenue for the quarter reached -$11.26M .
TNGX Stock Performance
Access detailed TNGX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.